Compare WYFI & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WYFI | DRUG |
|---|---|---|
| Founded | 2023 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 826.4M | 856.4M |
| IPO Year | N/A | 2020 |
| Metric | WYFI | DRUG |
|---|---|---|
| Price | $16.91 | $80.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $34.38 | ★ $114.00 |
| AVG Volume (30 Days) | ★ 692.4K | 77.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $65.86 | N/A |
| Revenue Next Year | $126.84 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.91 | $23.18 |
| 52 Week High | $40.75 | $123.75 |
| Indicator | WYFI | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 45.95 | 45.86 |
| Support Level | $15.36 | $77.80 |
| Resistance Level | $19.49 | $91.00 |
| Average True Range (ATR) | 1.37 | 5.45 |
| MACD | -0.15 | -0.25 |
| Stochastic Oscillator | 28.77 | 33.77 |
Whitefiber Inc is a provider of artificial intelligence infrastructure solutions. The company owns high-performance computing data centers and provide cloud-based HPC graphics processing units services, which it terms cloud services, for customers such as AI application and machine learning developers. Its Tier-3 data centers provide hosting and colocation services. Its cloud services support generative AI workstreams, especially training and inference. It has two reportable segments: cloud services and colocation services. The cloud services segment generates revenue from providing high performance computing services to support generative AI workstreams. Colocation services generate revenue by providing customers with physical space, power and cooling within the data center facility.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.